Tolerability and safety of fluvoxamine and other antidepressants.

International Journal of Clinical Practice
H G M Westenberg, C Sandner

Abstract

Selective serotonin [5-hydroxytryptamine (5-HT)] reuptake inhibitors (SSRIs) and the 5-HT noradrenaline reuptake inhibitor, venlafaxine, are mainstays in treatment for depression. The highly specific actions of SSRIs of enhancing serotonergic neurotransmission appears to explain their benefit, while lack of direct actions on other neurotransmitter systems is responsible for their superior safety profile compared with tricyclic antidepressants. Although SSRIs (and venlafaxine) have similar adverse effects, certain differences are emerging. Fluvoxamine may have fewer effects on sexual dysfunction and sleep pattern. SSRIs have a cardiovascular safety profile superior to that of tricyclic antidepressants for patients with cardiovascular disease; fluvoxamine is safe in patients with cardiovascular disease and in the elderly. A discontinuation syndrome may develop upon abrupt SSRI cessation. SSRIs are more tolerable than tricyclic antidepressants in overdose, and there is no conclusive evidence to suggest that they are associated with an increased risk of suicide. Although the literature suggests that there are no clinically significant differences in efficacy amongst SSRIs, treatment decisions need to be based on considerations such...Continue Reading

References

Oct 1, 1992·Clinical Pharmacology and Therapeutics·J van HartenA Cournot
Jan 1, 1990·Progress in Neuro-psychopharmacology & Biological Psychiatry·S P TyrerH W Griffiths
Jan 1, 1990·Clinical Neuropharmacology·S A MontgomeryD Montgomery
Jan 1, 1989·Annals of the New York Academy of Sciences·M H Fernstrom
Jan 1, 1985·Psychopharmacology·K Fredericson OverøJ P Gylding-Sabroe
Sep 1, 1982·The American Journal of Psychiatry·M D Gross
Jan 1, 1995·International Clinical Psychopharmacology·I Hindmarch
Jan 1, 1993·Journal of Toxicology. Clinical Toxicology·F S Messiha
Mar 1, 1993·Clinical Pharmacokinetics·J van Harten
Jan 1, 1995·European Archives of Psychiatry and Clinical Neuroscience·W HewerW F Gattaz
Oct 1, 1996·Journal of Clinical Psychopharmacology·N J CouplandJ P Potokar
Dec 1, 1996·International Clinical Psychopharmacology·C D Bouwer, B H Harvey
Feb 1, 1997·Psychopharmacology·R J Salin-Pascual, M L Moro-Lopez
Aug 1, 1997·The Journal of Clinical Psychiatry·R J Salín-PascualR Drucker-Colín
Nov 10, 1998·Journal of Psychopharmacology·P J Goodnick, B J Goldstein
Nov 17, 1998·International Clinical Psychopharmacology·K Brøsen
Dec 23, 1998·International Clinical Psychopharmacology·J J StrikH M Van Praag
Feb 6, 1999·Journal of Clinical Psychopharmacology·R C RosenM Menza
Apr 8, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·S M FogelmanD J Greenblatt
Apr 22, 1999·Journal of Clinical Psychopharmacology·C L AlfaroL Ereshefsky
Jul 13, 1999·The Journal of Clinical Psychiatry·J ZajeckaC M Beasley
Jul 14, 1999·Journal of Affective Disorders·G ChouinardM C O'Neill
Aug 17, 1999·The British Journal of Psychiatry : the Journal of Mental Science·G IsacssonU Bergman
Oct 3, 1999·Journal of Clinical Psychopharmacology·C de MontignyD Bakish
Feb 16, 2000·Pharmacology & Therapeutics·C Hiemke, S Härtter
May 10, 2000·Clinical Neuropharmacology·B H Harvey, C D Bouwer
May 29, 2000·The British Journal of Psychiatry : the Journal of Mental Science·D MichelsonR G Tepner
Jun 16, 2000·The Journal of Allergy and Clinical Immunology·G G Kay
Oct 6, 2000·Acta Psychiatrica Scandinavica. Supplementum·S PerettiI Hindmarch
Dec 1, 2000·Depression and Anxiety·J P Staab, D L Evans

❮ Previous
Next ❯

Citations

Jul 3, 2009·International Journal of Clinical Practice·I Hindmarch
Feb 3, 2009·Neuropsychiatric Disease and Treatment·Domenico De BerardisFilippo Maria Ferro
Feb 1, 2007·Neuropsychiatric Disease and Treatment·Fumihiko Okada
Feb 3, 2007·Expert Opinion on Drug Metabolism & Toxicology·John L BlackDavid A Mrazek
Mar 3, 2015·Expert Opinion on Drug Metabolism & Toxicology·Alfredo Carlo AltamuraMassimiliano Buoli
May 5, 2012·Clinical Therapeutics·Silvia RaveraJohan J de Gier
Sep 8, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Johanna HilliKari Laine
Sep 2, 2008·Acta Neurologica Scandinavica·D Kondziella, F Asztely
Sep 12, 2015·The Lancet. Psychiatry·Roisin O'SullivanDavid Meagher
Sep 14, 2012·Expert Opinion on Pharmacotherapy·Jennifer A ReinholdKarl Rickels
Aug 12, 2009·The Australian and New Zealand Journal of Psychiatry·Isaac SchweitzerChee Ng
Nov 13, 2012·The Australian and New Zealand Journal of Psychiatry·Chris P StephensonIain S McGregor
Dec 17, 2008·Journal of Psychopharmacology·G M Goodwin
Jul 29, 2006·Drugs & Aging·Paola SarchielliPaolo Calabresi
Feb 8, 2019·Journal of Basic and Clinical Physiology and Pharmacology·Junaidi KhotibUNKNOWN Suharjono
Jun 11, 2020·International Journal of Molecular Sciences·Nikoletta AlmásiKrisztina Kupai
Jun 2, 2009·Clinical Neuropharmacology·Maria Cristina Mendoza, J P Lindenmayer
May 24, 2017·European Journal of Drug Metabolism and Pharmacokinetics·Momir MikovHani Al-Salami
Oct 14, 2020·Scientific Reports·Ga Eun KimYong-Wook Shin
Feb 8, 2021·Progress in Neuro-psychopharmacology & Biological Psychiatry·Vincenzo OlivaAlessandro Serretti
Jun 6, 2021·Journal of Pharmaceutical Sciences·Akeemat O TijaniAshana Puri

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.